Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Incyte gains after data presentations

Incyte (NASDAQ:INCY) gained $1.92 (20%) to $11.39 on Tuesday after reporting data

Read the full 121 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE